Corium International (CORI) Stock Rating Lowered by BidaskClub

Corium International (NASDAQ:CORI) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Tuesday.

Several other research analysts also recently weighed in on CORI. Zacks Investment Research downgraded shares of Corium International from a “buy” rating to a “hold” rating in a research note on Thursday, April 5th. ValuEngine raised shares of Corium International from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Corium International in a research note on Friday, May 18th. Finally, HC Wainwright set a $14.00 target price on shares of Corium International and gave the company a “buy” rating in a research note on Friday, February 9th. Two analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Corium International currently has a consensus rating of “Buy” and an average price target of $13.00.

Corium International opened at $8.20 on Tuesday, MarketBeat reports. The firm has a market cap of $307.55 million, a PE ratio of -5.00 and a beta of 1.61. The company has a debt-to-equity ratio of 1.89, a current ratio of 8.11 and a quick ratio of 7.95. Corium International has a 52-week low of $6.25 and a 52-week high of $13.93.

Corium International (NASDAQ:CORI) last released its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). The firm had revenue of $10.06 million for the quarter, compared to analyst estimates of $7.07 million. Corium International had a negative return on equity of 273.01% and a negative net margin of 156.05%. analysts expect that Corium International will post -1.53 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in CORI. MetLife Investment Advisors LLC acquired a new position in Corium International in the 4th quarter valued at about $123,000. DekaBank Deutsche Girozentrale acquired a new position in Corium International in the 1st quarter valued at about $167,000. California Public Employees Retirement System acquired a new position in Corium International in the 4th quarter valued at about $310,000. Two Sigma Advisers LP acquired a new position in Corium International in the 4th quarter valued at about $317,000. Finally, Goldman Sachs Group Inc. raised its stake in Corium International by 126.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 18,416 shares during the last quarter. 95.13% of the stock is owned by hedge funds and other institutional investors.

Corium International Company Profile

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply